Home › Hepatitis B › NCT04588077

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

\- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \< 10 mIU/ml) will be recruited.

Exclusion Criteria:

* Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
* Those who had previous exposure to hepatitis B.
* Post liver transplant patients.
* Less than 18 years old.

About the study

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

What is being tested

• Heplisav-B Injectable Product, 2-dose regimen (biological)
• Heplisav-B Injectable Product, 3-dose regimen (biological)

Sponsor: Mercy Medical Center · Participants: 200 · Started: Sep 14, 2020

Contact the study team

• CHAU TO, MD · Phone: (714)-400-1331
• Paul Thuluvath, MD · Phone: (410)-332-9308

Official record on ClinicalTrials.gov — NCT04588077

Locations in the U.S.

Conditions

• Hepatitis B
• Cirrhosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.